BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Adimab, Inc. Announces New Discovery Programs with Eli Lilly and Company (LLY), Genentech (RHHBY) and Human Genome Sciences, Inc. (HGSI)


12/15/2010 7:17:06 AM

LEBANON, N.H.--(BUSINESS WIRE)-- Adimab, Inc., a technology leader in the discovery of fully human antibodies, today announced the initiation of three new independent research collaborations with Eli Lilly, Genentech, and Human Genome Sciences. Over the past 18 months Adimab has established collaborations with several leading Pharmaceutical companies including: Merck, Roche, Novartis, Pfizer, and now Eli Lilly, Genentech, and Human Genome Sciences.

“As more companies develop therapeutic leads against the same validated disease targets, leading Pharma companies are actively seeking out technologies that give them a meaningful advantage and Adimab’s deal flow speaks for itself,” said Tillman Gerngross, Adimab’s CEO and co-founder. “In this highly competitive environment, having access to the best technology becomes essential, not optional. Our ability to provide high quality leads in a matter of months is driving the demand for our technology.”

In addition to the three new collaborations, Adimab announced the achievement of a technical milestone in its ongoing collaboration with Novartis, which was initiated in June of 2010. Adimab also announced that Merck has exercised its option to start an additional project around a 2nd target.

“Adimab’s platform is unique in comparison to any other antibody discovery technology. By incorporating target biology into the selection process we are able to generate very high quality leads in a short timeframe,” said Guy Van Meter, Adimab’s Senior Director of Business Development. “The most sophisticated buyers in the industry understand the impact Adimab could have on their pipelines. Since launching the platform in June of 2009, we have closed a total of 15 funded discovery programs, including 10 new programs in 2010.”

About Adimab’s New Discovery Deals

Adimab and Lilly have entered into a collaboration whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against two targets selected by Lilly. For each target, the agreement grants Lilly the right to research antibodies generated from the collaboration for potential use as therapeutic products. Under the terms of the agreement, Adimab will receive various upfront fees including research fees and technical milestones. In addition, for each target, Lilly will have the sole option to exclusively license antibodies from the collaboration, and if Lilly were to exercise the option for a particular target, then Adimab would receive license fees, clinical milestones and royalties on therapeutic product sales for such target.

Adimab and Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) have initiated a research program whereby Adimab will use its proprietary yeast-based antibody discovery platform to identify fully human antibodies against two targets selected by Genentech. Under the terms of the agreement, Genentech has rights to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments, preclinical milestones and licensing fees. In addition, Adimab is eligible to receive clinical development milestones and royalties on therapeutic and diagnostic product sales.

Adimab and Human Genome Sciences, of Rockville MD, have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against one target selected by Human Genome Sciences. The agreement gives Human Genome Sciences the option to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments and preclinical milestones. In addition, Adimab is eligible to receive clinical development milestones and royalties on product sales.

About Adimab

Adimab’s integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressibility. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements. For more information, visit http://www.adimab.com.


Read at Xconomy
Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES